Japan will expand the eligibility criteria for the designation of “drugs for specific use” to include new active ingredients and introduce a framework allowing pharmaceutical companies to request designation themselves from May. The Ministry of Health, Labor and Welfare (MHLW)…
To read the full story
Related Article
- MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026
- MHLW to Add Company-Driven Route to “Specific-Use Drug” Designations
December 16, 2025
REGULATORY
- Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
- Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
- Tepezza Price Cut Set at 5.5% under Japan’s CEA Scheme
August 6, 2026
- Dupixent Faces Fourth Re-Pricing under Japan’s SPA-SSS
August 6, 2026
- Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





